Inhibrx Biosciences, Inc.

8-K · inhibrx-20260603.htm iXBRL

0002007919 2026-06-03 2026-06-03

 UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549  

 FORM 8-K

 CURRENT REPORT
 Pursuant to Section 13 or 15(d)
 of the Securities Exchange Act of 1934
 Date of Report (Date of earliest event reported): June 3, 2026

 INHIBRX BIOSCIENCES, INC.
 (Exact name of registrant as specified in its charter)  

 Delaware 001-42031 99-0613523
 (State or other jurisdiction
of incorporation) (Commission
File Number) (IRS Employer
Identification No.)

 11025 N. Torrey Pines Road , Suite 140
 La Jolla , CA 92037
 (Address of Principal Executive Offices and Zip Code)
 Registrant’s telephone number, including area code: ( 858 ) 795-4220

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 ☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 ☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 ☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 Securities registered pursuant to Section 12(b) of the Act:

 Title of each class Trading Symbol(s) Name of each exchange on which registered
 Common Stock, par value $0.0001 per share INBX The Nasdaq Global Market

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 Emerging growth company   ☒
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☒

 Item 5.07    Submission of Matters to a Vote of Security Holders.
 The 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Inhibrx Biosciences, Inc. (the “Company”) was held on June 3, 2026 at 10:00 a.m. Pacific Time online in a virtual format. Of the Company’s 14,607,286 shares of common stock issued and outstanding and entitled to vote as of the record date of April 7, 2026, a quorum of 11,541,232 shares, or approximately 79% of the outstanding shares entitled to vote, was present virtually or represented by proxy. Each of the matters set forth below is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 23, 2026. The following actions were taken at the Annual Meeting:
 Proposal 1
 Election of the following nominees as Class II directors of the Company, nominated by the Company’s Board of Directors (the “Board of Directors”), each to serve until the 2029 Annual Meeting of Stockholders and until their respective successor is duly elected and qualified, or until their respective earlier death, resignation, or removal.

 Votes For Votes Withheld Broker Non-Votes
 Douglas G. Forsyth 7,608,469 1,463,474 2,469,289
 Kimberly Manhard 9,035,097 36,846 2,469,289

 Proposal 2
 Ratification of the appointment by the Audit Committee of the Board of Directors of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

 Votes For Votes Against Votes Abstained
 11,510,478 30,347 407

 SIGNATURES
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Date: June 3, 2026
 INHIBRX BIOSCIENCES, INC.

 By: /s/ Leah Pollema
 Name: Leah Pollema
 Title: VP, General Counsel and Corporate Secretary